Retatrutide considerations Retatrutide , the triple agonist targeting GLP-1, GIP, and glucagon receptors, is still in clinical trials but early data provides insight into its injection site reaction profile
Side effects may include nausea, vomiting, diarrhea, constipation, and stomach pain, most are mild and decrease over time as dosing is titrated
It is a dual-action medication because it acts as both a GLP-1 receptor agonist and a GIP receptor agonist, thereby mimicking two hormones that play a crucial role in regulating appetite
W.CutlerR
11 Impact on PharmD/CDCES: Pharmacists/CDCES can help identify patients that would most benefit from tirzepatides A1c lowering and weight reducing effects Pharmacists/CDCES can provide appropriate patient counseling regarding tirzepatides administration, benefits, adverse drug reactions, and storage Pharmacists/CDCES can assist other healthcare providers to safely transition patients from a GLP-1 RA to tirzepatide Pharmacists can facilitate insurance/cost barriers for eligible patients based on approved indications References: Type 2 diabetes treatment to lower A1C: Mounjaro(tirzepatide).Mounjaro